ΔFVC% at PC20 AMP is negatively correlated with response to 6 weeks fluticasone treatment in asthma

E. J. M. Weersink, R. W. R. Douma, D. S. Postma (Amsterdam, Groningen, The Netherlands)

Source: Annual Congress 2002 - Indirect challenges
Session: Indirect challenges
Session type: Oral Presentation
Number: 2622
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. J. M. Weersink, R. W. R. Douma, D. S. Postma (Amsterdam, Groningen, The Netherlands). ΔFVC% at PC20 AMP is negatively correlated with response to 6 weeks fluticasone treatment in asthma. Eur Respir J 2002; 20: Suppl. 38, 2622

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004

Symptoms, induced sputum eosinophil percentages and treatment with salmeterol or fluticasone in mild asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 336s
Year: 2001

Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days
Source: Eur Respir J 2002; 20: Suppl. 38, 197s
Year: 2002

Comparison between fluticasone and salmeterol plus fluticasone on functional responses and sputum eosinophilia induced by allergen challenge
Source: Eur Respir J 2005; 26: Suppl. 49, 123s
Year: 2005

Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 317s
Year: 2006

Combined treatment with fluticasone plus salmeterol protects against allergen induced asthmatic responses and subsequent increase in sputum eosinophils
Source: Eur Respir J 2002; 20: Suppl. 38, 189s
Year: 2002

The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Combined treatment with fluticasone plus salmeterol protects against allergen-induced asthmatic responses better than each drug alone
Source: Eur Respir J 2001; 18: Suppl. 33, 349s
Year: 2001

Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma
Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment
Year: 2008



Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Sustained release theophylline added to fluticasone propionate in the treatment of paediatric asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old
Source: Eur Respir J 2003; 22: Suppl. 45, 535s
Year: 2003

Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 710s
Year: 2004

Asthma total costs reduction and clinical improvement after inhaled steroid shift to fluticasone propionate during 1 year in patients with moderate to severe asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 56s
Year: 2002

The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up
Source: Eur Respir J 2005; 26: Suppl. 49, 369s
Year: 2005